Dr. Reddy's Laboratories announced today that it has launched Hervycta (Trastuzumab ), a biosimilar of Roche's Herceptin in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer).

Dr. Reddy's Hervycta is available in strengths of 150mg and 440mg multiple dose vials.

MV Ramana, CEO- Branded Markets (India and Emerging Markets), Dr. Reddy's Laboratories, said, "We strive every day to do what matters most for patients. Hervycta is a step forward in our effort to accelerate access to cancer patients in India, in the Oncology biosimilar space."

Raymond De Vre, Senior Vice President and Head, Biolo_gics, Dr. Reddy's Laboratories added "The launch of Hervycta will immensely benefit women in India who are suffering from HER2-positive breast cancer and are in need of access to high quality, affordable and innovative medicines."

Herceptin (marketed as Herdon™ in India) and its biosimilars had India sales of approximately Rs 2.90 billion MAT for the most recent twelve months ending in December 2017, according to lpsos.

Dr. Reddy's currently has four biosimilar products commercialized in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.

Shares of the company gained Rs 12, or 0.57%, to trade at Rs 2,101.00. The total volume of shares traded was 10,881 at the BSE (9.24 a.m., Thursday).